NCT06592664 - Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC | Biotech Hunter

Timeline

Start Date

January 31, 2030

Primary Completion Date

January 31, 2035

Study Completion Date

January 31, 2040

Conditions

Pancreas CancerPancreatic CarcinomaPancreas AdenocarcinomaPancreatic Ductal AdenocarcinomaUnresectable Pancreatic CancerMetastatic Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

certepetide

certepetide given as an IV push over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

DRUG

nab-paclitaxel

nab-paclitaxel 125 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

DRUG

gemcitabine

gemcitabine 1000 mg/m\^2 IV administered on Day 1, 8, and 15 every 28 days

DRUG

placebo matching certepetide

placebo given as two IV pushes over 1 minute and as an IV infusion over 4 hours when standard treatment(s) are given

DRUG

certepetide

certepetide given as two IV pushes over 1 minute when standard treatment(s) are given

DRUG

placebo matching certepetide

placebo given as an IV infusion over 4 hours when standard treatment(s) are given

DRUG

placebo matching certepetide

certepetide given as a slow IV push over 1 minute when standard treatment(s) are given